nach oben

Erschienen in:

17.10.2018 | Original Article

Physical activity and exercise during preoperative pancreatic cancer treatment

verfasst von: Nathan H. Parker, An Ngo-Huang, Rebecca E. Lee, Daniel P. O’Connor, Karen M. Basen-Engquist, Maria Q.B. Petzel, Xuemei Wang, Lianchun Xiao, David R. Fogelman, Keri L. Schadler, Richard J. Simpson, Jason B. Fleming, Jeffrey E. Lee, Gauri R. Varadhachary, Sunil K. Sahai, Matthew H.G. Katz

Erschienen in: Supportive Care in Cancer | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Guidelines recommend exercise to cancer survivors, but limited data exists regarding exercise among patients undergoing preoperative cancer treatment. We examined differences in weekly self-reported exercise and accelerometer-measured physical activity among participants in a home-based exercise program administered during preoperative treatment for pancreatic cancer.

Methods

Participants were encouraged to perform at least 60 min/week of moderate-intensity aerobic exercise and at least 60 min/week of full-body strengthening exercises concurrent with chemotherapy, chemoradiation therapy or both sequentially and received resistance equipment, program instruction, and biweekly follow-up calls to encourage adherence. Self-reported aerobic and strengthening exercise minutes were measured using daily logs, and physical activity was measured objectively using accelerometers.

Results

Fifty participants (48% female, mean age 66 ± 8 years) participated for an average of 16 ± 9 preoperative weeks. Participants reported overall means of 126 ± 83 weekly minutes of aerobic exercise and 39 ± 33 weekly minutes of strengthening exercise in daily logs. Participants performed 158.7 ± 146.7 weekly minutes of accelerometer-measured moderate-to-vigorous physical activity. There were no significant differences in exercise or physical activity between treatment phases.

Conclusions

These findings suggest that it is feasible to target the entire preoperative course for exercise prescription. Although participants exceeded aerobic exercise recommendations on average, we observed low strengthening exercise adherence and wide variability in self-reported exercise and accelerometer physical activity variables. These findings suggest that additional support, including program adaptations, may be necessary to overcome barriers to exercise or improve motivation when prescribing exercise in this clinical scenario.

Brown JK, Byers T, Doyle C, Coumeya KS, Demark-Wahnefried W, Kushi LH, McTieman A, Rock CL, Aziz N, Bloch AS, Eldridge B, Hamilton K, Katzin C, Koonce A, Main J, Mobley C, Morra ME, Pierce MS, Sawyer KA (2003) Nutrition and physical activity during and after cancer treatment: an American Cancer Society guide for informed choices. CA Cancer J Clin 53(5):268–291CrossRefPubMed

Schmitz KH, Courneya KS, Matthews C, Demark-Wahnefried W, Galvao DA, Pinto BM, Irwin ML, Wolin KY, Segal RJ, Lucia A, Schneider CM, von Gruenigen VE, Schwartz AL (2010) American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc 42(7):1409–1426. https://doi.org/10.1249/MSS.0b013e3181e0c112 CrossRefPubMed

Cooper AB, Holmes HM, des Bordes JK, Fogelman D, Parker NH, Lee JE, Aloia TA, Vauthey JN, Fleming JB, Katz MH (2014) Role of neoadjuvant therapy in the multimodality treatment of older patients with pancreatic cancer. J Am Coll Surg 219(1):111–120. https://doi.org/10.1016/j.jamcollsurg.2014.02.023 CrossRefPubMed

Antoun S, Borget I, Lanoy E (2013) Impact of sarcopenia on the prognosis and treatment toxicities in patients diagnosed with cancer. Curr Opin Support Palliat Care 7(4):383–389. https://doi.org/10.1097/spc.0000000000000011 CrossRefPubMed

Cooper AB, Slack R, Fogelman D, Holmes HM, Petzel M, Parker N, Balachandran A, Garg N, Ngo-Huang A, Varadhachary G, Evans DB, Lee JE, Aloia T, Conrad C, Vauthey JN, Fleming JB, Katz MH (2014) Characterization of anthropometric changes that occur during neoadjuvant therapy for potentially resectable pancreatic cancer. Ann Surg Oncol 22(7):2416–2423. https://doi.org/10.1245/s10434-014-4285-2 CrossRefPubMed

Fleming JB, Gonzalez RJ, Petzel MQ, Lin E, Morris JS, Gomez H, Lee JE, Crane CH, Pisters PW, Evans DB (2009) Influence of obesity on cancer-related outcomes after pancreatectomy to treat pancreatic adenocarcinoma. Arch Surg (Chicago, Ill : 1960) 144(3):216–221. https://doi.org/10.1001/archsurg.2008.580 CrossRef

National Cancer Institute (2015) Pancreatic cancer treatment. http://www.cancer.gov/cancertopics/pdq/treatment/pancreatic/HealthProfessional/page5. Accessed March 16 2015

Bachmann J, Michalski CW, Martignoni ME, Buchler MW, Friess H (2006) Pancreatic resection for pancreatic cancer. HPB 8(5):346–351. https://doi.org/10.1080/13651820600803981 CrossRefPubMedPubMedCentral

Huang JJ, Yeo CJ, Sohn TA, Lillemoe KD, Sauter PK, Coleman J, Hruban RH, Cameron JL (2000) Quality of life and outcomes after pancreaticoduodenectomy. Ann Surg 231(6):890–898CrossRefPubMedPubMedCentral

10.

Park JW, Jang JY, Kim EJ, Kang MJ, Kwon W, Chang YR, Han IW, Kim SW (2013) Effects of pancreatectomy on nutritional state, pancreatic function and quality of life. Br J Surg 100(8):1064–1070. https://doi.org/10.1002/bjs.9146 CrossRefPubMed

11.

Cloyd JM, Tran Cao HS, Petzel MQ, Denbo JW, Parker NH, Nogueras-Gonzalez GM, Liles JS, Kim MP, Lee JE, Vauthey JN, Aloia TA, Fleming JB, Katz MH (2017) Impact of pancreatectomy on long-term patient-reported symptoms and quality of life in recurrence-free survivors of pancreatic and periampullary neoplasms. J Surg Oncol 115(2):144–150. https://doi.org/10.1002/jso.24499 CrossRefPubMed

12.

Cooper AB, Tzeng CW, Katz MH (2013) Treatment of borderline resectable pancreatic cancer. Curr Treat Options in Oncol 14(3):293–310. https://doi.org/10.1007/s11864-013-0244-6 CrossRef

13.

Tempero MA, Malafa MP, Behrman SW, Benson AB 3rd, Casper ES, Chiorean EG, Chung V, Cohen SJ, Czito B, Engebretson A, Feng M, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Lowy AM, Ma WW, Merchant NB, Mulvihill SJ, Muscarella P 2nd, Nakakura EK, Obando J, Pitman MB, Reddy S, Sasson AR, Thayer SP, Weekes CD, Wolff RA, Wolpin BM, Burns JL, Freedman-Cass DA (2014) Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. J Natl Compr Cancer Netw 12(8):1083–1093CrossRef

14.

Katz MH, Pisters PW, Evans DB, Sun CC, Lee JE, Fleming JB, Vauthey JN, Abdalla EK, Crane CH, Wolff RA (2008) Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 206(5):833–846CrossRefPubMedPubMedCentral

15.

West MA, Loughney L, Barben CP, Sripadam R, Kemp GJ, Grocott MP, Jack S (2014) The effects of neoadjuvant chemoradiotherapy on physical fitness and morbidity in rectal cancer surgery patients. Eur J Surg Oncol 40(11):1421–1428. https://doi.org/10.1016/j.ejso.2014.03.021 CrossRefPubMed

16.

Sahai SK, Ismail H (2015) Perioperative implications of neoadjuvant therapies and optimization strategies for cancer surgery. Curr Anesthesiol Rep 5(3):305–317CrossRef

17.

Silver JK (2015) Cancer prehabilitation and its role in improving health outcomes and reducing health care costs. Semin Oncol Nurs 31(1):13–30. https://doi.org/10.1016/j.soncn.2014.11.003 CrossRefPubMed

18.

Silver JK, Baima J (2013) Cancer prehabilitation: an opportunity to decrease treatment-related morbidity, increase cancer treatment options, and improve physical and psychological health outcomes. Am J Phys Med Rehabil 92(8):715–727. https://doi.org/10.1097/PHM.0b013e31829b4afe CrossRefPubMed

19.

Carli F, Scheede-Bergdahl C (2015) Prehabilitation to enhance perioperative care. Anesthesiol Clin 33(1):17–33. https://doi.org/10.1016/j.anclin.2014.11.002 CrossRefPubMed

20.

Kim BJ, Caudle AS, Gottumukkala V, Aloia TA (2016) The impact of postoperative complications on a timely return to intended oncologic therapy (RIOT): the role of enhanced recovery in the cancer journey. Int Anesthesiol Clin 54(4):e33–e46. https://doi.org/10.1097/aia.0000000000000113 CrossRefPubMed

21.

Padilha CS, Marinello PC, Galvao DA, Newton RU, Borges FH, Frajacomo F, Deminice R (2017) Evaluation of resistance training to improve muscular strength and body composition in cancer patients undergoing neoadjuvant and adjuvant therapy: a meta-analysis. J Cancer Surviv 11(3):339–349. https://doi.org/10.1007/s11764-016-0592-x CrossRefPubMed

22.

Loughney L, West MA, Kemp GJ, Grocott MP, Jack S (2016) Exercise intervention in people with cancer undergoing neoadjuvant cancer treatment and surgery: a systematic review. Eur J Surg Oncol 42(1):28–38. https://doi.org/10.1016/j.ejso.2015.09.027 CrossRefPubMed

23.

Ngo-Huang A, Parker NH, Wang X, Petzel MQB, Fogelman D, Schadler KL, Bruera E, Fleming JB, Lee JE, Katz MHG (2017) Home-based exercise during preoperative therapy for pancreatic cancer. Langenbeck's Arch Surg 402:1175–1185. https://doi.org/10.1007/s00423-017-1599-0 CrossRef

24.

PancFit: multimodal exercise during preoperative therapy for pancreatic cancer. (2017). https://clinicaltrials.gov (Identification No. NCT02295956)

25.

British Columbia Ministry of Health (1992) Physical activity readiness questionnaire. British Columbia, Canada

26.

Katz MHG, Pisters PWT, Evans DB, Sun CC, Lee JE, Fleming JB, Vauthey JN, Abdalla EK, Crane CH, Wolff RA, Varadhachary GR, Hwang RF (2008) Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 206(5):833–846. https://doi.org/10.1016/j.jamcollsurg.2007.12.020 CrossRefPubMedPubMedCentral

27.

Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr (2004) Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 291(20):2441–2447. https://doi.org/10.1001/jama.291.20.2441 CrossRefPubMed

28.

Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol 5(6):649–655CrossRefPubMed

29.

Huffman GB (2002) Evaluating and treating unintentional weight loss in the elderly. Am Fam Physician 65(4):640–650PubMed

30.

Lim KH, Chung E, Khan A, Cao D, Linehan D, Ben-Josef E, Wang-Gillam A (2012) Neoadjuvant therapy of pancreatic cancer: the emerging paradigm? Oncologist 17(2):192–200. https://doi.org/10.1634/theoncologist.2011-0268 CrossRefPubMedPubMedCentral

31.

Borg G (1970) Perceived exertion as an indicator of somatic stress. Scand J Rehabil Med 2(2):92–98PubMed

32.

US Dept. of Health and Human Services (2008) Physical activity guidelines for Americans. US Dept. of Health and Human Sercies, Centers for Disease Control and Prevention, National Center for Disease Prevention and Health Promotion. http://www.health.gov/paguidelines/guidelines/. Accessed 9 April 2018

33.

Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML, Ainsworth BE, Pratt M, Ekelund U, Yngve A, Sallis JF, Oja P (2003) International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 35(8):1381–1395. https://doi.org/10.1249/01.mss.0000078924.61453.fb CrossRefPubMed

34.

Conroy T, Desseigne F, Ychou M, Ducreux M, Bouche O, Guimbaud R, Becouarn Y, Montoto-Grillot C, Gourgou-Bourgade S, Adenis A (2010) Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial. J Clin Oncol 28(15_suppl):4010–4010CrossRef

35.

Ward DS, Evenson KR, Vaughn A, Rodgers AB, Troiano RP (2005) Accelerometer use in physical activity: best practices and research recommendations. Med Sci Sports Exerc 37(11 Suppl):S582–S588CrossRefPubMed

36.

Troiano RP, Berrigan D, Dodd KW, Masse LC, Tilert T, McDowell M (2008) Physical activity in the United States measured by accelerometer. Med Sci Sports Exerc 40(1):181–188. https://doi.org/10.1249/mss.0b013e31815a51b3 CrossRefPubMed

37.

Freedson PS, Melanson E, Sirard J (1998) Calibration of the computer science and applications, Inc. accelerometer. Med Sci Sports Exerc 30(5):777–781CrossRefPubMed

38.

Whitley E, Ball J (2002) Statistics review 6: nonparametric methods. Crit Care 6(6):509–513CrossRefPubMedPubMedCentral

39.

Gillis C, Li C, Lee L, Awasthi R, Augustin B, Gamsa A, Liberman AS, Stein B, Charlebois P, Feldman LS, Carli F (2014) Prehabilitation versus rehabilitation: a randomized control trial in patients undergoing colorectal resection for cancer. Anesthesiology 121(5):937–947. https://doi.org/10.1097/aln.0000000000000393 CrossRefPubMed

40.

LeMasters TJ, Madhavan SS, Sambamoorthi U, Kurian S (2014) Health behaviors among breast, prostate, and colorectal cancer survivors: a US population-based case-control study, with comparisons by cancer type and gender. J Cancer Surviv 8(3):336–348. https://doi.org/10.1007/s11764-014-0347-5 CrossRefPubMedPubMedCentral

41.

Riebe D, Blissmer BJ, Greaney ML, Garber CE, Lees FD, Clark PG (2009) The relationship between obesity, physical activity, and physical function in older adults. J Aging Health 21(8):1159–1178. https://doi.org/10.1177/0898264309350076 CrossRefPubMed

42.

Loprinzi PD, Davis RE (2016) Bouted and non-bouted moderate-to-vigorous physical activity with health-related quality of life. Prev Med Rep 3:46–48. https://doi.org/10.1016/j.pmedr.2015.12.005 CrossRefPubMed

43.

Copeland JL, Esliger DW (2009) Accelerometer assessment of physical activity in active, healthy older adults. J Aging Phys Act 17(1):17–30CrossRefPubMed

44.

Trost SG, O'Neil M (2014) Clinical use of objective measures of physical activity. Br J Sports Med 48(3):178–181. https://doi.org/10.1136/bjsports-2013-093173 CrossRefPubMed

45.

Hardcastle SJ, Cohen PA (2017) Effective physical activity promotion to survivors of cancer is likely to be home based and to require oncologist participation. J Clin Oncol 35(32):3635–3637. https://doi.org/10.1200/jco.2017.74.6032 CrossRefPubMed

Titel: Physical activity and exercise during preoperative pancreatic cancer treatment
verfasst von: Nathan H. Parker
An Ngo-Huang
Rebecca E. Lee
Daniel P. O’Connor
Karen M. Basen-Engquist
Maria Q.B. Petzel
Xuemei Wang
Lianchun Xiao
David R. Fogelman
Keri L. Schadler
Richard J. Simpson
Jason B. Fleming
Jeffrey E. Lee
Gauri R. Varadhachary
Sunil K. Sahai
Matthew H.G. Katz
Publikationsdatum: 17.10.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Supportive Care in Cancer / Ausgabe 6/2019
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-018-4493-6

Neu im Fachgebiet Onkologie

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

23.05.2024 Leitsymptome in der Hausarztpraxis Nachrichten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Physical activity and exercise during preoperative pancreatic cancer treatment

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

Das sind die führenden Symptome junger Darmkrebspatienten

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

Update Onkologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2019

Medication-related osteonecrosis of the jaw incidence in patients exposed concomitantly to bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors: is it generalizable to all solid tumors?

Caring for the person with cancer and the role of digital technology in supporting carers

Emotional talk of patients with breast cancer during review appointments with therapeutic radiographers: effects on fears of cancer recurrence

Open-label placebo reduces fatigue in cancer survivors: a randomized trial

Distress and quality of life in patient and caregiver dyads facing stem cell transplant: identifying overlap and unique contributions

Prognostication in advanced cancer: update and directions for future research

Neu im Fachgebiet Onkologie

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

Das sind die führenden Symptome junger Darmkrebspatienten

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

Update Onkologie